Exploring the BM resident plasma and immune microenvironment cells, Zavidij et al. found evidence of increased natural killer cell proportions, altered chemokine receptor expression upon disease progression [15] and myeloma-associated events, such as loss of granzyme K+ (GZMK) memory cytotoxic T cells and major histocompatibility complex class II dysregulation in CD14 + monocytes, in the premalignant stages. This evidence concerns the gene GZMK and plasma cell myeloma.